Deals

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035
ADC / XDCAdlai Nortye

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035

Adlai Nortye (NASDAQ: ANL) announced that it has separately entered into clinical trial collaboration and drug supply agreements with Eli Lilly and Company (NYSE: LLY) and Merck KGaA, Darmstadt, Germany…

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China
ETR: MRKMerck

Zelgen Bio Collaborates with Merck KGaA for rhTSH Promotion in China

Lancet Robotics Secures Series A+ Funding for Surgical Robot Development
FinanceLancet Robotics

Lancet Robotics Secures Series A+ Funding for Surgical Robot Development

Bayer's Vividion Gains Global Rights to WRN Inhibitor VVD-214
BayerETR: BAYN

Bayer’s Vividion Gains Global Rights to WRN Inhibitor VVD-214

Nanjing Leads Biolabs Files for Hong Kong IPO Amid Product Pipeline Progress
IPOLeads Biolabs

Nanjing Leads Biolabs Files for Hong Kong IPO Amid Product Pipeline Progress

Show More